UA112423C2 - Спосіб одержання (варіанти) кристалічних форм розувастатину тба - Google Patents

Спосіб одержання (варіанти) кристалічних форм розувастатину тба

Info

Publication number
UA112423C2
UA112423C2 UAA201308185A UAA201308185A UA112423C2 UA 112423 C2 UA112423 C2 UA 112423C2 UA A201308185 A UAA201308185 A UA A201308185A UA A201308185 A UAA201308185 A UA A201308185A UA 112423 C2 UA112423 C2 UA 112423C2
Authority
UA
Ukraine
Prior art keywords
preparation
pharmaceutical intermediates
purity pharmaceutical
intermediates
purity
Prior art date
Application number
UAA201308185A
Other languages
English (en)
Inventor
Лакс Дьордь Кованіне
Дьюла Шіміг
Балаж Волк
Ференц Лорант Барта
Дьордь Краснай
Дьордь Ружікс
Ева Шіпош
Кальман Надь
Дьордь Моров'ян
Йожеф Баркоці
Адріенн Кестей
Янош Імре
Габор Багінскі
Original Assignee
Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг filed Critical Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Publication of UA112423C2 publication Critical patent/UA112423C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Даний винахід стосується проміжних сполук, що корисні при одержанні фармацевтично прийнятних солей (+)-7-[4-(4-фторфеніл)-6-ізопропіл-2-(метансульфонілметиламіно)-піримідин-5-іл]-(3R,5S)-дигідроксигепт-6-енової кислоти, і поліморфів зазначених проміжних сполук, способів їх одержання і їх застосування.
UAA201308185A 2010-11-29 2011-11-29 Спосіб одержання (варіанти) кристалічних форм розувастатину тба UA112423C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1000637A HU230987B1 (hu) 2010-11-29 2010-11-29 Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
PCT/HU2011/000113 WO2012073055A1 (en) 2010-11-29 2011-11-29 Method for the preparation of high-purity pharmaceutical intermediates

Publications (1)

Publication Number Publication Date
UA112423C2 true UA112423C2 (uk) 2016-09-12

Family

ID=89990088

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201308185A UA112423C2 (uk) 2010-11-29 2011-11-29 Спосіб одержання (варіанти) кристалічних форм розувастатину тба

Country Status (15)

Country Link
US (1) US9133132B2 (uk)
EP (1) EP2646420A1 (uk)
JP (1) JP2013543884A (uk)
CN (1) CN103298793B (uk)
AU (1) AU2011334661A1 (uk)
BR (1) BR112013013169A2 (uk)
CA (1) CA2818314A1 (uk)
EA (1) EA029079B1 (uk)
HU (1) HU230987B1 (uk)
IL (1) IL226301A0 (uk)
MX (1) MX2013005961A (uk)
NZ (1) NZ610765A (uk)
UA (1) UA112423C2 (uk)
WO (1) WO2012073055A1 (uk)
ZA (1) ZA201303467B (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
HU229260B1 (en) 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN103709107B (zh) * 2012-09-29 2016-04-20 安徽省庆云医药化工有限公司 瑞舒伐他汀甲酯的新晶型及其制备方法
CN103848790B (zh) * 2012-12-05 2016-08-03 安徽省庆云医药化工有限公司 瑞舒伐他汀酯的晶型及其制备方法
CN106531756B (zh) * 2016-10-28 2018-05-18 中国计量科学研究院 探测器阳极装置
CN110483412B (zh) * 2019-09-17 2020-06-26 安徽省庆云医药股份有限公司 一种瑞舒伐他汀叔丁酯的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2003228010A1 (en) 2002-05-21 2003-12-02 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
AU2002348881A1 (en) 2002-12-10 2004-06-30 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2004103977A2 (en) * 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
EP1709008A1 (en) 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
CA2573857A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
TWI345562B (en) * 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20090124803A1 (en) 2005-03-22 2009-05-14 Pandurang Balwant Deshpande Process for preparation of rosuvastatin
EP1869005A1 (en) 2005-04-04 2007-12-26 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
CN1872841A (zh) * 2005-06-01 2006-12-06 信谊药厂 瑞舒伐他汀钙及其关键中间体的制备方法
US9150518B2 (en) * 2005-06-24 2015-10-06 Lek Pharmaceuticals, D.D. Process for preparing amorphous rosuvastatin calcium of impurities
US8207333B2 (en) 2005-06-24 2012-06-26 Lek Pharmaceuticals D. D. Process for preparing pure amorphous rosuvastatin calcuim
CZ299215B6 (cs) 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
WO2007040940A1 (en) * 2005-10-03 2007-04-12 Teva Pharmaceutical Industries Ltd. Diastereomeric purification of rosuvastatin
WO2007099561A1 (en) 2006-02-27 2007-09-07 Cadila Healthcare Limited Process for preparing rosuvastatin calcium
HU227696B1 (en) 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
WO2007125547A2 (en) 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
EP2066644A2 (en) * 2006-08-04 2009-06-10 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
WO2008038132A1 (en) 2006-09-28 2008-04-03 Aurobindo Pharma Limited Crystalline diamine salts of rosuvastatin
EP2086945B1 (en) * 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US20100069635A1 (en) 2006-11-29 2010-03-18 Dr. Reddy's Laboratories Ltd. Rosuvastatin dehydroabietylamine salt
US8094450B2 (en) 2007-06-22 2012-01-10 Cole Kepro International, Llc Gaming machine vent cover
EP2022784A1 (en) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
WO2009118598A1 (en) * 2008-03-24 2009-10-01 Aurobindo Pharma Limited Process for the manufacture of rosuvastatin calcium with high purity
WO2009143776A1 (zh) * 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
CN102282136B (zh) * 2009-01-14 2014-12-17 新梅斯托克尔卡·托瓦纳·兹德拉维尔公司 制备罗苏伐他汀的方法
US8507513B2 (en) 2009-01-15 2013-08-13 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for the preparation of rosuvastatin salts
US8846915B2 (en) * 2009-08-17 2014-09-30 Aurobindo Pharma Ltd. Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
AU2011243948B2 (en) 2010-04-23 2014-07-17 Sun Pharmaceutical Industries Limited Novel intermediates for the preparation of HMG-CoA reductase inhibitors
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts

Also Published As

Publication number Publication date
WO2012073055A1 (en) 2012-06-07
EP2646420A1 (en) 2013-10-09
IL226301A0 (en) 2013-07-31
MX2013005961A (es) 2013-07-29
BR112013013169A2 (pt) 2020-10-13
NZ610765A (en) 2015-06-26
EA201390771A1 (ru) 2013-11-29
CN103298793A (zh) 2013-09-11
US20130338360A1 (en) 2013-12-19
JP2013543884A (ja) 2013-12-09
ZA201303467B (en) 2014-07-30
CN103298793B (zh) 2016-06-22
HU1000637D0 (en) 2011-02-28
HU230987B1 (hu) 2019-08-28
AU2011334661A1 (en) 2013-06-13
CA2818314A1 (en) 2012-06-07
US9133132B2 (en) 2015-09-15
EA029079B1 (ru) 2018-02-28
HUP1000637A2 (en) 2012-05-29

Similar Documents

Publication Publication Date Title
NZ609957A (en) Heterocyclic compounds and uses thereof
UA112423C2 (uk) Спосіб одержання (варіанти) кристалічних форм розувастатину тба
PH12015501965A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
EP2387561A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
PH12014502040A1 (en) Heterocyclyl compounds
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
MY175854A (en) Novel quinolone derivatives
MX341482B (es) Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
MY180039A (en) N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
MX2013005960A (es) Metodo para preparar sales de rosuvastatina.
MX2014016054A (es) N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas como antagonistas del receptor de androgenos, su produccion y usos como productos medicinales.
UY33893A (es) Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
NZ630251A (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
WO2012011129A3 (en) Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
MX2010011006A (es) Nueva sal de un derivado de pirimidina.
EA201290051A1 (ru) Кристаллическая форма i соли розувастатина цинка
EA201390700A1 (ru) Кристаллические фармацевтически активные ингредиенты
AU2013204155B2 (en) Pure erlotinib
UA106710C2 (uk) Сполука 2-(2,4,5-заміщеного аніліно)піримідину та її застосування для лікування раку